Company Overview
- Potential broad treatment for solid malignancies that express Kiromic-developed biomarkers such as Iso-mesothelin.
- Solid tumors represent ~90% of new cancer diagnoses but finding specific targets to treat them has been challenging.
- Kiromic tackles the issue by identifying new cancer-specific targets.
- In-house cGMP manufacturing
- In-house QC/EM lab
- In-house product and process development (R&D and MSAT)
- Outpatient treatment means reduced hospitalization and other treatment-related costs.
- Lower projected cost increases patient and health care professional access to these therapies, and potentially provides important quality-of-life benefits for patients as well.
- Strong efficacy demonstrated in preclinical animal models.
- In solid tumors, the benefit of infiltrating conventional T cells may vary.
- In contrast, GDT cells are the infiltrating immune cells most likely to be associated with positive outcomes, as shown in an analysis of 18,000 tumors from 39 indications1